KWF/Alpe d'HuZes grant for cancer on chip

Thursday, 17 August 2017

An hDMT team led by researcher Dik van Gent (Erasmus MC) has received a grant from the Dutch Cancer Foundation (KWF) and financed by the Alpe d'HuZes funding scheme. The project team will develop a cancer-on-chip device that allows relatively long term culturing of (breast) tumor tissue.

Project information

Title: Developing a validated Cancer-on-Chip prototype for personalized medicine

Description: Cancer is a very heterogeneous disease: many different types of tumors exist and even not all tumor cells in one tumor are the same. This is a big problem for clinical decision making. How should we treat each individual tumor and how exactly does the tumor react to such a treatment? These questions are difficult to address when the tumor is still inside the body, but could be answered more readily if we can grow the tissue outside the body, where we can image the tissue using microscopic techniques. Therefore, we aim to develop the technology to make this possible. The project brings together (medical) biologists, engineers and the company Genmab, who will work together on creating a working and validated 'cancer-on-chip' prototype that can be used in future projects for personalized medicine, as well as for asking fundamental questions about cancer biology. The project is unique in bringing together these expertises and it is high risk, because it is difficult to predict what the optimal technological set up will be. However, the options for further research will be enormous if the project teams succeed in its endeavor.

Project team

PI: Dr. Dik van Gent, Department of Molecular Genetics, Erasmus MC

Academic partners: Prof. dr. Jaap den Toonder (Department of Mechanical Engineering, TU Eindhoven); Dr. Erik Danen (Leiden Academic Center for Drug Research (LACDR), Leiden University), Prof. Dr. Ronald Dekker (Department of Microelectronics, TU Delft), Prof. Dr. Jos Jonkers (Department of Molecular Pathology, Netherlands Cancer Institute) and Dr. John Martens (Department of Medical Oncology, Erasmus MC)

Private partner: Genmab

Project duration: 18 months

Project funding: € 170,420

Back to the news overview